MedTrace Logo

Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients

NCT00615966 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2011-06-29

No results posted yet for this study

Summary

The purpose of this study is evaluate the safety and tolerability of Diannexin in kidney transplant recipients.

Conditions

  • Kidney Transplantation

Interventions

DRUG

Diannexin

single dose, 200 µg/kg IV

DRUG

Placebo

Single dose, IV

DRUG

Diannexin

Single dose, 400 µg/kg IV

Sponsors & Collaborators

  • CTI Clinical Trial and Consulting Services

    collaborator OTHER

  • Alavita Pharmaceuticals Inc

    lead INDUSTRY

Principal Investigators

  • Stuart Knechtle, MD · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2009-01-31
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00615966 on ClinicalTrials.gov